Blueprint exec spots key Ayvakit readout, dealmaking plan as 'independent precision therapy company'
Blueprint Medicines has been a possible buyout target for large pharma companies thanks to its attractive precision cancer therapy focus. But some of the Massachusetts biotech’s recent moves suggest ...
An Ayvakit trial win in the rare blood disorder of indolent systemic mastocytosis could be an inflection point for Blueprint Medicines’ commercial business. The company now has positive trial data to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback